Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GT Biopharma, Inc. - Common Stock (NQ:GTBP)

0.6276 -0.0218 (-3.36%)
Streaming Delayed Price Updated: 9:52 AM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GT Biopharma, Inc. - Common Stock

News headline image
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
Via ACCESS Newswire
News headline image
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
From GT Biopharma, Inc.
Via GlobeNewswire
News headline image
GT Biopharma Announces Adjournment of Special Shareholders Meeting
From GT Biopharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.